Skip to main content

Advertisement

Table 3 Five-year overall survival and relapse-free survival of 69 patients who received Paclitaxel/Carboplatin

From: Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

  5y OS (95% CI) P* 5y RFS (95% CI) P*
All patients (n = 69) 87% (78–96) no of deaths: 7   79% (69–89) no of relapses: 14  
Stage   .81   .28
Ia, Ib (n = 16) 94% (82–100) No of deaths: 1   93% (79–100) No of relapses: 1  
Ic, II (n = 53) 86% (75–97) No of deaths: 6   78% (66–90) No of relapses: 13  
Grade   .88   .30
1 (n = 12) 92% (76–100) No of deaths: 1   92% (76–100) No of relapses: 1  
2,3 (n = 54) 86% (75–97) No of deaths: 6   78% (66–90) No of relapses: 13  
Ia/Ib OR grade 1 (n = 28) 93% (83–100) No of deaths: 2 .58 92% (82–100) No of relapses: 2 .03
Ic/II AND grade2/3 (n = 39) 84% (71–97) No of deaths: 5   73%(58–88) No of relapses: 12  
  1. *p values estimated with log rank test